Telix Pharmaceuticals is focused on the development and commercialisation of several clinical-stage oncology assets in renal cancer, prostate cancer, and glioblastoma. We are also actively exploring indication expansion opportunities for our programs as they reflect targeting approaches that may be relevant to other clinical applications.

Our lead program, a Positron Emission Tomography (PET) agent for imaging clear cell renal cell carcinoma (ccRcc), is in Phase III and delivers a major unmet need in the diagnosis and staging of kidney cancer. We are also developing a number of mid-stage molecularly-targeted products in prostate cancer and glioblastoma (brain cancer) with significant commercial and clinical potential.

Telix Images-08

Learn more about Telix Assets

Click the button to see more details about TX250, TX591 and TX101